168160-77-8 Usage
Uses
Used in Pharmaceutical Industry:
2-Ethoxycarbonylmethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester is used as a building block for the development of new drugs, particularly in the synthesis of bioactive molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, 2-Ethoxycarbonylmethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester serves as a precursor for the synthesis of a wide range of compounds, taking advantage of its stability and reactivity.
Used as a Protecting Group:
As a tert-butyl ester, 2-Ethoxycarbonylmethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester can be used as a protecting group in organic synthesis, allowing chemists to temporarily mask functional groups during complex reactions, ensuring selective reactions and facilitating the synthesis of target molecules.
Overall, 2-Ethoxycarbonylmethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester is an important compound with diverse potential applications in the field of organic chemistry and pharmaceutical research, offering a foundation for the development of innovative drugs and synthetic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 168160-77-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,8,1,6 and 0 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 168160-77:
(8*1)+(7*6)+(6*8)+(5*1)+(4*6)+(3*0)+(2*7)+(1*7)=148
148 % 10 = 8
So 168160-77-8 is a valid CAS Registry Number.
168160-77-8Relevant articles and documents
HETEROCYCLIC COMPOUNDS
-
Page/Page column 18, (2009/02/11)
The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
-
Page/Page column 47, (2008/06/13)
The present invention is directed to compounds of formula (I): Wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, Rs